Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Lymphoma, B-Cell Clinical Trial

Official title:

A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04884035
• Other study ID #: CC-220-DLBCL-001
• Secondary ID: 2020-005705-71
• Status: Recruiting
• Phase: Phase 1
• Start date: September 15, 2021
• Est. completion date: February 4, 2026

Study information

• Verified date: February 2024
• Source: Celgene
• Contact: BMS Study Connect Contact Center www.BMSStudyConnect.com
• Phone: 855-907-3286
• Email: Clinical.Trials[@]bms.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP-21); CC-220 and R-CHOP-21 or CC-99282 and R-CHOP-21. Part 1 will be followed by a randomized dose expansion (Part 2) with CC-220 and/or CC-99282 at the Recommended Phase 2 Dose (RP2D) in combination with R-CHOP-21. A polatuzumab-R-CHP regimen in combination with CC-220 or CC-99282 will be explored with the addition of a new cohort only after the RP2D for the CC-220 and/or CC-99282 and R-CHOP-21 combination has been defined.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 174
• Est. completion date: February 4, 2026
• Est. primary completion date: June 10, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants must satisfy the following criteria to be enrolled in the study:

1. Is = 18 years of age at the time of signing the informed consent form (ICF).

2. Participant has histologically confirmed (per local evaluation) diagnosis of de novo, previously untreated, a-BCL according to 2016 WHO classification.

3. Participant has International Prognostic Index (IPI) score 0-5 in Part 1 and IPI 2-5 in Part 2. For the CELMoD and polatuzumab-R-CHP cohort, the subject must also have IPI score 0 to 5 in Part 2A and IPI 2 to 5 in Part 2B.

4. Participants must have measurable disease defined by at least one FDG-avid lesion for FDG-avid subtype and one bi-dimensionally measurable (> 1.5 cm in longest diameter) disease by computed tomography (CT) or magnetic resonance imaging (MRI), as defined by the Lugano classification (Cheson, 2014).

5. Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

6. Participants must have the following laboratory values:

1. Absolute neutrophil count (ANC) = 1.5 x 109/L or = 1.0 x 109/L in case of documented bone marrow involvement (> 50% or tumor cells), without growth factor support for 7 days (14 days if peg-G-CSF)

2. Hemoglobin (Hb) = 8 g/dL

3. Platelets (PLT) = 75 x 109/L or = 50 x 109/L in case of documented bone marrow involvement (>50% or tumor cells), without transfusion for 7 days

4. Aspartate aminotransferase / serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase / serum glutamate pyruvic transaminase (ALT/SGPT) = 2.5 x upper limit of normal (ULN). In the case of documented liver involvement by lymphoma, ALT/SGPT and AST/SGOT must be = 5.0 x ULN.

5. Serum total bilirubin = 2.0 mg/dL except in cases of Gilbert's syndrome, then = 5.0 mg/dl. Subjects receiving polatuzumab vedotin must have serum total bilirubin < 1.5 × ULN (26 µmol/L) (corresponding to mild degree as per National Cancer Institute Organ Dysfunction Working Group [NCI ODWG] criteria) except in cases of Gilbert's syndrome, then = 3.0 mg/dl (51 µmol/L).

6. Estimated serum creatinine clearance (CrCl) of = 50 mL/min using the modification of diet in renal disease (MDRD) formula.

7. All participants must:

1. Have an understanding that the study drug could have a potential teratogenic risk.

2. Agree to follow all requirements defined in the Pregnancy Prevention Program for CC-220 or CC-99282 Pregnancy Prevention Plan for Participants in Clinical trials.

8. Females of childbearing potential (FCBP) must:

a. Have two negative pregnancy tests as verified by the investigator prior to starting study therapy.

9. Male participants must:

1. Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study.

Exclusion Criteria:

• The presence of any of the following will exclude a participant from enrollment:

1. Any significant medical condition, active infection (including SARS-CoV-2 suspected or confirmed), laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study.

2. Any condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study.

3. Any other subtype of lymphoma.

4. Documented or suspected CNS involvement by lymphoma.

5. Persistent diarrhea or malabsorption = Grade 2 (NCI CTCAE v5.0), despite medical management.

6. Peripheral neuropathy = Grade 2 (NCI CTCAE v5.0).

7. Subjects with a history of progressive multifocal leukoencephalopathy.

8. Chronic systemic immunosuppressive therapy or corticosteroids

9. Impaired cardiac function or clinically significant cardiac disease, including any of the following:

a. Left ventricular ejection fraction (LVEF) < 45% as determined by multigated acquisition (MUGA) scan or echocardiogram (ECHO)

10. Major surgery = 2 weeks prior to starting CC-220 or CC-99282; participant must have recovered from any clinically significant effects of recent surgery.

11. Any condition causing inability to swallow tablets.

12. Known seropositivity for or active viral infection with human immunodeficiency virus (HIV)

13. Known chronic active hepatitis B (hepatitis B virus surface antigen [HBsAg] positive and/or hepatitis B core antibody [anti-HBc] positive with viral DNA positive) or C (positive serology requiring treatment and/or with evidence of liver damage) infection

14. History of other malignancy, unless being free of the disease for = 3 years; exceptions to the = 3-year time limit include history of the following:

1. Localized nonmelanoma skin cancer

2. Carcinoma in situ of the cervix

3. Carcinoma in situ of the breast

4. Incidental histologic finding of prostate cancer (T1a or T1b as per Tumor Node Metastasis [TNM] staging system) or prostate cancer that has been treated with curative intent.

15. Hypersensitivity to the active substance or to murine proteins, or to any of the other excipients of rituximab or polatuzumab vedotin.

16. Known hypersensitivity to any component of CHOP/CHP regimen.

17. Known allergy to thalidomide, pomalidomide, or lenalidomide.

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, B-Cell

Intervention

Drug:
• CC-220
CC-220 by mouth at the assigned dose starting on Day 1 for 14 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
• Rituximab
Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion or 1400 mg (SC) subcutaneous (from Cycle 2) of a 21-day treatment cycle for up to a total of 6 cycles
• Cyclophosphamide
Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
• Doxorubicin
Doxorubicin 50 mg/m2 IV infusion on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
• Vincristine
Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) IV intravenous on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
• Prednisone
Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
• CC-99282
CC-99282 by mouth at the assigned dose starting on Day 1 for 7 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
• Polatuzumab vedotin
Polatuzumab vedotin 1.8 mg/kg on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
• Rituximab
Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles

Locations

Country	Name	City	State
Australia	Local Institution - 501	Adelaide	South Australia
Australia	Local Institution - 503	Perth
Australia	Local Institution - 502	Waratah
Greece	General Hospital of Athens "Laiko"	Athens
Greece	Local Institution - 701	Athens
Greece	Local Institution - 702	Athens
Greece	Local Institution - 703	Patras
Greece	Georgios Papanikolaou General Hospital of Thessaloniki	Thessaloniki
Korea, Republic of	Local Institution - 300	Seoul
Korea, Republic of	Local Institution - 301	Seoul
Korea, Republic of	Local Institution - 302	Seoul
Poland	Local Institution - 601	Gdansk
Poland	MCM Krakow - PRATIA - PPDS	Krakow
Poland	Centrum Medyczne Pratia Poznan	Poznan
Poland	Local Institution - 0706	Poznan
Poland	Local Institution - UNK0706	Poznan
Poland	SP ZOZ Szpital Uniwersytecki w Krakowie	Slomniki
Poland	Local Institution - 602	Warsaw
Poland	Local Institution - 604	Wroclaw
Spain	Hospital Universitari Germans Trias i Pujol ICO Badalona	Barcelona
Spain	Local Institution - 204	Madrid
Spain	H. Virgen de la Victoria	Málaga
Spain	Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca	Salamanca
Taiwan	Local Institution - 402	Taichung
Taiwan	Local Institution - 403	Taichung
Taiwan	Local Institution - 400	Taipei
United States	Roswell Park Cancer Institute	Buffalo	New York
United States	MD Anderson Cancer Center	Houston	Texas
United States	Mayo Clinic - Jacksonville	Jacksonville	Florida
United States	Mayo Clinic Jacksonville - PPDS	Jacksonville	Florida
United States	University Of Kansas Medical Center	Kansas City	Kansas
United States	University of Nebraska - Fred and Pamela Buffet Center	Omaha	Nebraska
United States	Mayo Clinic - Rochester	Rochester	Minnesota
United States	Mayo Clinic - Arizona	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Celgene

Countries where clinical trial is conducted

United States,  Australia,  Greece,  Korea, Republic of,  Poland,  Spain,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose (MTD) - Part 1	Frequency of dose-limiting toxicities (DLT) associated with addition of iberdomide (CC-220) to R-CHOP-21 therapy and the addition of CC-99282 to R-CHOP-21 therapy	During the first 2 cycles of treatment (each cycle is 21 days)
Primary	Recommended Phase 2 Dose (RP2D) - Part 1	Defined as the dose that will be selected for dose expansion based on MTD	During the first cycle of treatment (each cycle is 21 days)
Primary	Safety and tolerability of CC-220 and CC-99282 at RP2D - Part 2	AEs evaluated using NCI CTCAE criteria, v. 5.0, including treatment -emergent adverse events (TEAEs) and laboratory assessments	From the first dose of any IP until 28 days after the last dose of IP
Primary	Maximum Tolerated Dose (MTD) - Part 2A	Frequency of DLTs associated with addition of iberdomide (CC-220) to polatuzumab-R-CHP therapy and the addition of CC-99282 to polatuzumab-R-CHP therapy	During the first cycle of treatment (each cycle is 21 days)
Primary	Recommended Phase 2 Dose (RP2D) - Part 2A	Defined as the dose that will be selected for dose expansion based on MTD	During the first cycle of treatment (each cycle is 21 days)
Secondary	Best overall response rate (ORR)	The proportion of participants with best overall response achieved during the study as either Complete Response or Partial Response before subsequent anti-lymphoma therapy	Up to 4 years
Secondary	Complete Metabolic Response Rate (CMRR)	The proportion of participants experiencing complete metabolic response (CMR) before receiving any subsequent anti-lymphoma therapy	Up to 4 years
Secondary	Time to Response (TTR)	The time from entry to the study (enrollment date for Part 1 and randomization date for Part 2) to the date of first documented response (= PR)	Up to 4 years
Secondary	Duration of Response (DOR)	The time from the earliest date of documented response (= PR) to the first occurrence of relapse or progression	Up to 4 years
Secondary	Progression-free Survival (PFS)	The time from entry to the study (enrollment date for Part 1 and randomization date for Part 2) to the first occurrence of disease progression or death from any cause	Up to 4 years
Secondary	Overall Survival (OS)	The time from entry to the study (enrollment date for Part 1 and randomization date for Part 2) to death from any cause	Up to 4 years
Secondary	Pharmacokinetics - Cmax for CC-220	Maximum plasma concentration of drug	At Cycle 1 Day 7, Cycle 1 Day 15, and Cycle 2 Day 7 (each cycle is 21 days)
Secondary	Pharmacokinetics - Ctrough for CC-220	Minimum or trough concentration	At Cycle 1 Day 7, Cycle 1 Day 15, and Cycle 2 Day 7 (each cycle is 21 days
Secondary	Pharmacokinetics - Tmax for CC-220	Time to maximum plasma concentration	At Cycle 1 Day 7, Cycle 1 Day 15, and Cycle 2 Day 7 (each cycle is 21 days
Secondary	Pharmacokinetics - Cmax for CC-99282	Maximum plasma concentration	At Cycle 1 Day 7, Cycle 1 Day 15, and Cycle 2 Day 7 (each cycle is 21 days
Secondary	Pharmacokinetics - Ctrough for CC-99282	Minimum or trough concentration	At Cycle 1 Day 7, Cycle 1 Day 15, and Cycle 2 Day 7 (each cycle is 21 days
Secondary	Pharmacokinetics - Tmax for CC-99282	Time to maximum plasma concentration	At Cycle 1 Day 7, Cycle 1 Day 15, and Cycle 2 Day 7 (each cycle is 21 days

External Links

•   BMS Clinical Trial Information
•   BMS Clinical Trial Patient Recruiting